US Denies Approval for Creat's $1.5 Billion Acquisition of Germany's Biotest

02:56 EST 9 Nov 2017 | ChinaBio Today

Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest, a German blood plasma products corporation, because US regulators refused to approve the deal. According to Bloomberg, the Committee on Foreign Investment in the United States was worried that a China corporation would have access to US donor information. Creat and Biotest said the acquisition can not be completed under the current structure, but the two companies hope to forge a new agreement that will satisfy US regulators. More details....

Stock Symbol: (DE: BIOG)

Share this with colleagues:

Original Article: US Denies Approval for Creat's $1.5 Billion Acquisition of Germany's Biotest


More From BioPortfolio on "US Denies Approval for Creat's $1.5 Billion Acquisition of Germany's Biotest"

Quick Search


Relevant Topics

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...